XML 34 R24.htm IDEA: XBRL DOCUMENT v3.7.0.1
Collaboration Agreements - AstraZeneca Agreements - Additional Information 1 (Detail) - AstraZeneca Agreements [Member] - USD ($)
$ in Millions
3 Months Ended 6 Months Ended 12 Months Ended
Jul. 30, 2013
Sep. 30, 2016
Dec. 31, 2015
Jun. 30, 2017
Dec. 31, 2015
U.S./RoW [Member]          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]          
Expected upfront, non-contingent and time-based payments $ 374.0        
Development and regulatory approval milestones 550.0        
Commercial sales milestone 325.0        
Shared development costs     $ 233.0    
Additional consideration based on net sales description       Low 20% range  
U.S./RoW [Member] | FibroGen, Inc. [Member]          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]          
Shared development costs     $ 116.5    
U.S./RoW [Member] | Development Milestones [Member]          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]          
Receipt of development milestone payment         $ 15.0
China [Member]          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]          
Development and regulatory approval milestones 161.0        
Commercial sales milestone 167.5        
Proceeds from upfront payments 28.2        
Contingent payment $ 20.0        
Estimated joint development service period   2018      
Estimated joint development extended service period   2020